BMJ article on malpractice, Pfizer trials

  • Thread starter Thread starter pinball1970
  • Start date Start date
  • Tags Tags
    article
AI Thread Summary
Concerns regarding trial integrity in vaccine studies have emerged, particularly highlighted by a communication from Jackson to the FDA about Ventavia's handling of a significant trial. Issues raised include inadequate monitoring of participants post-injection, delayed follow-up on adverse events, unreported protocol deviations, improper vaccine storage, mislabelled specimens, and targeting of staff who reported these issues. While the overwhelming data supports the vaccine's efficacy, these concerns cast doubt on the integrity of the trials and the scientific community, especially from a taxpayer's viewpoint. However, many argue that while human error is inevitable in such processes, the major results remain reliable, as corroborated by real-world data. The problems identified are primarily procedural rather than indicative of fraud or data manipulation, and analyses suggest that these issues did not significantly impact trial outcomes.
pinball1970
Gold Member
Messages
3,500
Reaction score
5,484
TL;DR Summary
https://www.bmj.com/content/375/bmj.n2635

In her 25 September email to the FDA Jackson wrote that Ventavia had enrolled more than 1000 participants at three sites. The full trial (registered under NCT04368728) enrolled around 44 000 participants across 153 sites that included numerous commercial companies and academic centres. Many concerns raised.
Not what we want want to be reading in the BMJ at this time regarding trial integrity.
The Vaccine works, the data is overwhelming but this casts a shadow on the integrity of the trials and the Science community as a whole (especially seen from the tax payer/layman perspective)

Concerns raised​

In her 25 September email to the FDA Jackson wrote that Ventavia had enrolled more than 1000 participants at three sites. The full trial (registered under NCT04368728) enrolled around 44 000 participants across 153 sites that included numerous commercial companies and academic centres. She then listed a dozen concerns she had witnessed, including:
  • Participants placed in a hallway after injection and not being monitored by clinical staff
  • Lack of timely follow-up of patients who experienced adverse events
  • Protocol deviations not being reported
  • Vaccines not being stored at proper temperatures
  • Mislabelled laboratory specimens, and
  • Targeting of Ventavia staff for reporting these types of problems.
There is also a mention of patients being unblinded.

Science guys seen this? Thoughts? Or is the human factor that is part and parcel of the process?
Thanks in advance.
 
Biology news on Phys.org
pinball1970 said:
Science guys seen this? Thoughts? Or is the human factor that is part and parcel of the process?
Can't spell 'science' without 'humans'. Else who would spell it?
 
  • Like
Likes jim mcnamara, atyy and BillTre
To elaborate on my previous post, this isn't unexpected. Frankly I'd be amazed if no sites anywhere reported any of the problems listed above. People are flawed, fallible, and lazy. That's why the processes that inspect and report on said problems exist in the first place.
pinball1970 said:
The Vaccine works, the data is overwhelming but this casts a shadow on the integrity of the trials and the Science community as a whole (especially seen from the tax payer/layman perspective)
If its a shadow, it's a small one. There doesn't appear to be any fraud or tampering with data and results. Most of the issues listed have to do with people not doing all the little nitty gritty things that they're supposed to be doing. You don't want to know all the little things that I've seen get skipped, missed, and overlooked in my career in the Air Force.

Still, little things lead to big problems, so these obviously need to be addressed.
 
  • Like
Likes atyy and pinball1970
The major trial results were quantitatively corroborated by real world data from Israel.
It's unclear how most of the issues would have affected the trial results. One of the issues - the non-testing of symptomatic participants - that could have affected the trial results, was analyzed by Pfizer and the FDA and found not to affect results.
Another point of view: https://respectfulinsolence.com/2021/11/15/wtf-happened-to-the-bmj/
What @thackerpd didn't mention: The share of non-tested trial participants was very similar in the treatment and the placebo groups (9.2% vs 10.1%), and a sensitivity check was done on this issue. https://t.co/7g4B3AUqyG pic.twitter.com/q3DDySb2KG
— Andreas Backhaus (@AndreasShrugged) November 3, 2021
 
  • Informative
Likes pinball1970
Deadly cattle screwworm parasite found in US patient. What to know. https://www.usatoday.com/story/news/health/2025/08/25/new-world-screwworm-human-case/85813010007/ Exclusive: U.S. confirms nation's first travel-associated human screwworm case connected to Central American outbreak https://www.reuters.com/business/environment/us-confirms-nations-first-travel-associated-human-screwworm-case-connected-2025-08-25/...
Chagas disease, long considered only a threat abroad, is established in California and the Southern U.S. According to articles in the Los Angeles Times, "Chagas disease, long considered only a threat abroad, is established in California and the Southern U.S.", and "Kissing bugs bring deadly disease to California". LA Times requires a subscription. Related article -...
I am reading Nicholas Wade's book A Troublesome Inheritance. Please let's not make this thread a critique about the merits or demerits of the book. This thread is my attempt to understanding the evidence that Natural Selection in the human genome was recent and regional. On Page 103 of A Troublesome Inheritance, Wade writes the following: "The regional nature of selection was first made evident in a genomewide scan undertaken by Jonathan Pritchard, a population geneticist at the...
Back
Top